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Isolated from Annona squamosa L, Annonaceous acetogenins (ACGs) exhibit a broad range of biological properties yet absorbed
badly due to the low solubility. Solid dispersion in polyethylene glycol 4000 (PEG 4000) has been developed to increase the
solubility and oral absorption of ACGs. The formulation of ACGS-solid dispersion was optimized by a simplex lattice experiment
design and carried out by a solvent-fusion method. We studied the absorption property of ACGs in rat’s intestine, which showed
there was a good absorption and uptake percentages with solid dispersion. The study on uptake percentage in diﬀerent regions
of rat’s intestine attested that the duodenum had the best permeability, followed by jejunum, ileum, and colon in order with no
signiﬁcant diﬀerences. So the paper drew the conclusion that solid dispersion could improve the solubility and oral absorption of
annonaceous acetogenins.
1.Introduction
Annonaceous acetogenins (ACGs) constitute a group of
natural substances that may be isolated exclusively from
species of the family Annonaceae. The AGEs are one of the
most interesting classes of natural products appearing in the
past two decades. They exhibit a wide variety of biological
activities, and, impressively, some of which have strong
cytotoxic against various cancer cells. The Annonaceae is
comprisedofsome120generaandincludeover2100species;
most of the family is spread in tropics and subtropics. Many
of the tropical species bear edible fruits and have been
naturalized from central and South America to other warm
areas in Asia and Africa [1–3].
ACGs are white, waxy derivatives of long-chain (C32 or
C34) belonging to a series of C-35/C-37 natural products.
ACGsalwayspossessaterminalγ-lactoneringandaterminal
aliphatic side chain connected with some oxygen-bearing
moieties,suchasone-to-threetetrahydrofuran(THF)and/or
tetrahydropyran (THP) rings, which plays an important role
in determining the relative activities of the acetogenins [4–
6]. Recent studies have shown that the two functional units,
the central THF system ﬂanked by hydroxyl groups and the
terminal γ-lactone and also the alkyl chain that acts as a
spacer between them, play signiﬁcant roles in inhibiting the
enzyme [7, 8]. The ring systems can be single, adjacent, or
nonadjacent types, and these systems, with their ﬂanking
hydroxyls, create a number of chiral centers. A complex
mixture of diastereomers is the usual result.
ACGs are powerful cytotoxins and display in vivo
antitumor, pesticidal, antimalarial, anthelmintic, piscicidal,
antiviral, and antimicrobial properties. Commercial prod-
ucts include shampoo for treating infestations of head lice,
ﬂeas, and ticks, a series of pesticidal sprays, and an ointment
for the treatment of oral herpes (HSV-1) and other skin
aﬄictions [1]. As the potent inhibitors of mitochondrial
(complex I) as well as cytoplasmic production of adenosine
triphosphate (ATP) and related nucleotides, ACGs could
induce the programmed cell death process in tumors cells
at very low concentration. Although further studies of
the cellular processes involved in the modulation of the
selectivity of ACGs against the various tumor cells are
required, AGEs have been regarded as candidates for future
generations of antitumor drugs with diﬀerent mechanisms.
Besides,Derbr´ eetal.haveidentiﬁednewputativeprotein
targets of squamocin, an acetogenin of the Annonaceae,
ruling out the previously accepted “complex I dogma” [9].2 Gastroenterology Research and Practice
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Figure 1: The chemical structure of ACGs compounds.
These compounds are Complex I inhibitors, which play
an important role in the maintenance of the bioenergetic
function of the cell by driving the ATP synthesis from the
mitochondrial-reduced equivalents produced in the central
metabolic oxidative pathways [9–16].
We isolated and puriﬁed several ACGs from seeds of
Annona squamosa L. (sugar apple), such as annonacin,
squamocin, annonin-VI, and cherimolin-I (Figure 1), which
accounted for about 3.2%, 8%, 38%, and 9.2% in the total
extracts according to the previous study in our lab.
Chermolin-I and annonacin have mono-THF, whenever
squamocinandannonin-VIrepresentbis-THFtype.Thebis-
THF type compounds can be organized into three major
subtypes, and the squamocin and annonin-VI belonged
to annonin-VI subtype [1]. Degli Esposti et al. ﬁrst used
mammalian mitochondria to study the action of ACGs and
reported that annonin-VI inhibited the proton pumping
function of complex I with similar eﬃciency under steady-
stateandnonsteady-stateconditions[17].Besides,Yuanetal.
foundthatannonacincouldarrestT24bladdercancercellsat
the G1 phase and cause cytotoxicity in a Bax- and caspase-3-
related pathway [18]. Squamocin was also found to inhibit
the proliferation of K562 cells via G2/M arrest in association
with the induction of p21, p27 and the reduction of Cdk1
and Cdc25C kinase activities [19]. These works connected
the AGEs with cell apoptosis, which exploited the multiple
functions of AcGs as new anticancer candidates [20].
However, possessing various pharmacological eﬀects and
the antitumor activities in particular, ACGs were so poorly
soluble as to result in being not wellabsorbed after oral
administration. Therefore, the challenge of the pharmaceu-
tical technology lies in improving the water solubility of the
substances. Solid dispersions are one of the most promising
strategies to improve the oral bioavailability of poorly waterGastroenterology Research and Practice 3
soluble drugs. SD is deﬁned as the dispersion of one or more
active ingredients in an inert hydrophilic carrier or matrix
at solid state, prepared by the fusion, solvent, or the solvent-
fusionmethod [21–24].SD providesthe possibility to reduce
the drug particle size almost to the molecular level. Solid
dispersions are also one of the most successful strategies to
improve drug release of poorly soluble drugs, which can be
deﬁned as molecular mixtures of poorly water soluble drugs
in hydrophilic carriers, which present a drug release proﬁle
that is driven by the polymer properties [25–28].
The present study aims to investigate the absorption
of acetogenins-solid dispersion (ACGs-SD). Firstly, we pre-
pared several SDs containing diﬀerent proportions of PEG
4000 to obtain the best formulation. Then, permeability
studies were carried out with the rat in situ single-pass
intestinal perfusion model, as it has been shown to be
predictiveofinvivoabsorptioninhumans[29–36].Wechar-
acterizedtheintestinalabsorptionofACGs-SDbyexamining
the concentration of chermolin-I, annonacin, squamocin
and annonin-VI in rats intestinal perfusion solution. Then
we evaluated the absorption sites of ACGs-SD after oral
administration by a closed loop experiment.
2. Experimental
2.1. Chemicals, Reagents, and Animals. The native com-
pounds (ACGs) are kindly provided by natural department,
Institute of Medicinal Plant Development, Chinese Academy
of Medical Sciences, as well as the standard of cherimolin-
I, and annonacin, squamocin, annonin-VI (purity > 98%).
PEG4000 was purchased from Beijing Chemical Reagents
Co. Ltd (0051230). HPLC grade methanol was purchased
from Fisher Scientiﬁc Co. Ltd. (USA). Absolute alcohol
was analytical reagent grade, from the BEIJING SHIJI
(Beijing, China), and all other reagents were of analytical
grade. Sprague-Dawley rats (SCXK (jing) 2007-0001), male,
healthy,weighing250±20g,werepurchasedfromVitalRiver
Laboratory Animal Technology Co. Ltd. (Beijing, China) for
the animal experiment. Animals were kept in a normally
controlled breeding room with standard laboratory food
and water for one week prior to the experiments. The rats
were maintained in accordance with internationally accepted
principles for laboratory animal use and the study was
approved by the Beijing Animal Care Committee.
3. Methods
3.1. Preparation of the ACGs Solid Dispersion. Solid disper-
sionwaspreparedbysolvent-fusionmethod[22].5mgACGs
and 100mg PEG were accurately weighted and dissolved in
5mL of alcohol, and the solvent was evaporated under 40◦C
and freezed quickly under −80◦Cf o r2 ha n dt h e nd r i e d
under vacuum at room temperature for 20h. After being
dried, the sample was pulverized, sieved, and the fractions
≤100μm were selected.
3.2. High-Performance Liquid Chromatography (HPLC). The
exact content of the compounds, cherimolin-I, annonacin,
squamocin, annonin-VI, was determined using a pump
L7100, and a SHIMADZU SPD-10AVP UV-detector
(SHIMADAU, Japan). An SLC-10AVP (Shimadzu, Japan)
equipped with a C-18 reversed-phase chromatographic col-
umn (250 × 4.6mm; 5μm particle size) was used. The col-
umn was kept at 40◦C throughout the elution process, which
used a mobile phase consisting of acetonitrile and water at
a total ﬂow rate of 1.0mL · min−1 and the detection wave-
length set to 220nm. The system was run with a gradient
program set in Shimadzu LC solution workstation. Pump
B server for acetonitrile (solvent B): 0∼10min 29%∼29%
B, 10∼35min 27%∼27% B, 35∼45min 25%∼25% B, 45∼
55min 15%∼15% B, 55∼70min 29%∼29% B; injection vol-
ume: 20μL.
The method was fully validated for speciﬁcity, linearity,
LLOQ, accuracy, and precision. Control samples (QC) were
assessed by the procedure as described above to evaluate
speciﬁcity of the method.
3.2.1. Linearity. The calibration samples were prepared in
duplicates and assayed as described above. The calibration
equation was obtained by linear least-squares regression
analysis with the aid of Microsoft Excel.
3.2.2. Accuracy and Precision. QC samples in ﬁve replicates
were analyzed on the same day to determine the intra-
day precision and accuracy and on ﬁve consecutive days
to determine the inter-day precision and accuracy. The
concentration of each sample was determined by using the
calibration standards prepared on the same day.
3.2.3.Sensitivity. Sensitivitywasdeterminedbythedetection
limit (LLOD, three times of the value of the background
noise signal, S/N = 3) and the lowest quantiﬁcation limit
(LLOQ, ten times of the baseline noise, lowest concentration
of standard measurable).
3.2.4. Stability. The stability of sample solution was also
tested at room temperature and 4◦C, respectively, for
24h. For freeze-thaw stability testing, the samples were
determined after three freeze (−20◦C) and thaw (room
temperature) cycles, and the concentration was compared
to their nominal concentration. For the short-term stability,
the samples (three replicates at each QC concentration) were
extracted and placed at room temperature for 24h and then
injected into the HPLC system for analysis.
3.3. Solubility Studies. Solubility studies were conducted by
placing an excess amount of ACGs (approximately 15mg)
and ACG-solid dispersion in 10mL distilled water, and
the mixture was heated at 37 ± 0.5◦Ci naw a t e rb a t ht o
facilitate the solubilization using a vortex mixer. Mixtures
were equilibrated at 37 ± 0.5◦C for 72h in a water bath.
The equilibrated samples were centrifuged at 3000rpm for
15min to remove the undissolved material. The supernatant
was determined by HPLC.
3.4. Dissolution Studies. Dissolution studies were carried out
according to the Chinese Pharmacopoeia 2010 apparatus
No. 1 (paddle method) with a ZRS-4 dissolution apparatus4 Gastroenterology Research and Practice
(Tianjin, China). The concentration of each component is
determined by HPLC. 100mL of pH 6.8 phosphate buﬀer
was used as dissolution medium. The dissolution tests were
carried out at 37 ± 0.5◦C at a rotation speed of 100rpm.
Samples of 1mL were withdrawn at time intervals of 5, 10,
30, 60, and 120min. The volume of dissolution medium was
adjustedto100mLbyreplacingeach1mLaliquotwithdrawn
with 1mL of fresh dissolution medium. The solutions
were immediately ﬁltered through 0.45μm membrane ﬁlter.
Annonacin, squamocin, annonin-VI, and cherimolin-1 in
ACGs and ACGs-SD were studied similarly.
3.5. Single-Pass Intestinal Perfusion Studies (SPIP) in Rats.
We used male Sprague-Dawley rats weighing 250 ± 20g
for all perfusion studies. The drug solution was prepared
by dispersing the ACGs-SD in the K-R buﬀer solution and
installed in the cylinder, which was incubated in at 37◦C
water bath to maintain temperature.
The in situ SPIP experiment was conducted according
to the previously published reports [29, 30]. Firstly, six
male Sprague-Dawley rats were placed in respective cages
and fasted overnight before the experiment with free access
to water. Rats were anesthetized with an intraperitoneal
injection of pentobarbital sodium (40mg/Kg body weight,
i.p. injection), restrained in a supine position, and kept at a
body temperature of 37◦C using infrared lamps.
Bile duct was ligated and the intestinal content was
immediately washed away with 37◦C saline solution at a
ﬂow rate of 5mL/min, by cannulating polyethylene tubings
(3.2mm diameter) using a peristaltic pump (BT00-100M,
Baoding Longer Precision Pump Co., Ltd., China). The iso-
lated segment, duodenum, jejunum, ileum, and colon were
rinsed with physiological saline to clean any residual debris
until the out ﬂowing became colorless. Then, the intestinal
loop was made by ligating both ends of the intestinal loop
from 4cm below the bile duct opening to a segment above
the ileocecum of small intestine of anesthetized rats. Care
was taken to handle the small intestine gently in order to
maintain an intact blood supply. The whole surgical area
was covered with a piece of sterilized gauze wetted with
physiological saline solution.
ACGs-SD was dissolved in K-R buﬀer solution (0.35g
KCl, 1.37g NaHCO3, 7.8g NaCl, 0.22g NaH2PO4,0 . 0 2 g
MgCl2,andglucosein1.48g/1000mLpuriﬁedwater,pH6.5)
at a concentration of 200μg/mL, 300μg/mL, 500μg/mL of
ACGs, and the solution was administered to the loop via the
polyethylene tubing inserted into the loop. At the start of
the study, the perfusion buﬀer containing sample solution
was ﬁrst perfused at a ﬂow rate of 5mL/min to ensure
ﬁlling the segment rapidly, and the time was set to zero
with the immediate start of the perfusion and the solution
volume in circulation was recorded as the 0min volume.
After 10min, when steady-state condition was achieved, the
ﬂowratewasadjustedto0.2mL/min,andtheoutletperfused
samples were collected at time intervals (5, 10, 15, 30, 60,
90, 120min) for 2h. During 2h perfusion period, at each
time period, assemble the outlet solution. At the end of the
experiment, the length of perfused intestinal segment was
measured without stretching.
3.6. Eﬀects of Diﬀerent Intestinal Site on Intestinal Absorption.
SPIP was performed in diﬀerent intestinal segments (duo-
denum, jejunum, ileum, and colon segment) to test if the
diﬀerent intestinal showed varies absorption proﬁle [31, 32].
The study followed the method described in Li et al.
[32] and Dahan and Amidon [33]. Each 10cm long intesti-
nal segment was isolated as follows: duodenum segment
beginning from 1cm distal to pylorus, jejunum segment
beginning from 15cm away from pylorus, ileum segment
beginning at the site 20cm upwards caecum, while segment
colon beginning at the site 2cm distal to caecum. The above
segments were carefully cannulated and ligated with both
the ends. Then, each segment was perfused with solution
containing diﬀerent mass of ACGs.
3.7. Stability of ACGs in K-R Buﬀer Solution. Exact amount
of ACGs-SD was dissolved in K-R buﬀer solution at 37◦C
in water bath. Chermolin-1, annonacin, squamocin, and
annonin-VI were determined at 0, 30, 60, 90, and 120min
to analysis the stability of ACGs in K-R buﬀer solution.
3.8. Data Analysis. The eﬀective permeability (Ka, Papp)o f
the drug disappearing from the intestinal lumen during
the intestinal perfusion was calculated by the steady-state
equation:
Ka =
(1 −CoutQout/CinQin)Q
V
Papp =
[− Qin ·ln (CoutQout/CinQin)]
2πrL
(1)
where the radius of the gut lumen was represented by r,i t s
length by L, and the perfusate ﬂow rate by Q (mL/min).
V presents the volume of the tested intestinal. The fraction
Cout/Cin represents the concentration of the drμg leaving the
perfused segment (Cout) normalized to the concentration
entering the segment (Cin). The Cout values were corrected
for net water ﬂux by the gravimetric method [34].
Once the intestinal segment reached steady state, sub-
sequent values of Cout/Cin were used to calculate Papp. Papp
represents the permeability of the compound (cm/s) as
determined by the disappearance of the compound from the
intestinal lumen. Steady state was assumed to be reached
when Cout/Cin reached a constant value, as determined by
direct observation of the data [35].
3.9. Statistics. Statistical analyses were performed using
SPSS13. Statistical signiﬁcance was considered to be reached
at P<0.05.
4. Results and Discussion
4.1. Validation of HPLC Method
4.1.1. Speciﬁcity. As the Figure 2 shows, under the HPLC
condition, no interference peaks were observed from the K-
Rb u ﬀer solution as well as the pre-dose intestinal samples
from the SD rats which participated in the absorption study
of ACGs. This method provided a suﬃcient speciﬁcity.Gastroenterology Research and Practice 5
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Figure 2: HPLC Chromatograms of A: Cherimolin-1, B: annonacin, C: Squamocin, D: annonin-VI. (a) blank K-R buﬀer solution; (b) the
four compounds in ACGs extract.
Table 1: Stability test of ACGs during the storing and preparation
procedures.
Nominal
concentration
(ng/mL)
Accuracy (mean ± SD)%
Freeze-thaw
(three cycles)
Samples at room
temperature for 24h
Annonacin 96.0 ±1.09 6 .3 ±2.1
Squamocin 101.6 ±4.2 101.3 ±6.2
Annonin-VI 99.3 ±5.09 8 .3 ±2.1
Cherimolin-I 99.5 ±1.29 9 .1 ±2.1
4.1.2. Linearity. Calibration curves of ACGs were linear over
the concentration range of 0.5–80μg/mL. Good linearity
with a correlation coeﬃcient r2 = 0.999 was observed.
The representative regression equation was y = 14514x −
13358 (annonacin), y = 16939x − 7166.1 (squamocin),
y = 18691x + 4198.3 (annonin-VI), y = 16203x −
5353.1 (cherimolin-I), where y indicates the peak area of
compound, and x indicates the concentration.
4.1.3. Sensitivity. The LLOQ, deﬁned as the lowest quantiﬁ-
cation concentration, which can be detected in plasma was
0.5μg/mL. Similarly the LLOD was 0.2μg/mL.
4.1.4.Precision,Accuracy,andRecovery. Thismethodshowed
good precision and accuracy. The intra-day precisions were
measured to be 2.3%, 4.5%, 3.5% (annonacin), 2.2%, 3.2%,
2.7% (squamocin), 1.8%, 1.2%, 2.1% (annonin-VI), 1.8%,
1.6%, 2.6% (cherimolin-I), and the inter-day precisions were
measured to be 3.2%, 2.7%, 2.1% (annonacin), 1.9%, 1.2%,
2.4% (squamocin), 1.4%, 1.8%, 2.2% (annonin-VI), 1.4%,
1.6%, 1.5% (cherimolin-I).
The absolute recovery of ACGs from K-R buﬀer solution
was determined to be 98.2–101.2%, the relative recovery of
ACGs was determined to be 98.4–105.1%.
4.1.5. Stability. Stock solutions of ACGs were stable for at
least 30 days when stored at 4◦C. No signiﬁcant change
was found after three freeze-thaw cycles and stored at room
temperature for 24h (Table 1).
Table 2: Stability of ACGs in K-R buﬀer solution (n = 3).
Sample
Time (h)
RSD (%)
00 . 5 1 2
Annonacin 100% 98.63% 98.59% 96.16% 1.62
Squamocin 100% 100.51% 99.86% 98.58% 0.82
Annonin-VI 100% 95.64% 99.59% 85.83% 2.40
Cherimolin-I 100% 100.56% 99.58% 99.74% 0.42
4.2. Solubility Studies. The solubility of free AGCs is so
poor that the concentration is out of the lowest quan-
tiﬁcation limit of the analysis method, whereas the solid
dispersion technology increased the solubility of AGCs
remarkably. The solubility of annonacin is 213.11μg/mL,
squamocin is 1084.73μg/mL, annonin-VI is 249.54μg/mL,
and cherimolin-I is 99.33μg/mL. Solid dispersion could
reduce the drug particle size almost to the molecular to
enhance the solubility of drug. The data displayed that solid
dispersion could increase ACGs solubility signiﬁcantly.
4.3. In Vitro Dissolution Studies. It is important to improve
the drug solubility in the gastrointestinal tract to increase
the oral adsorption of poorly water soluble drugs. The four
compounds in ACGs-SD were stable in K-R buﬀer solution
for 2h (Table 2) and tested for dissolution properties, the
results shown in Figure 3. At each time point, the chemical
dissolved from the solid dispersion state was signiﬁcantly
higher than that of free ACGs. This proﬁle could ascribe to
the solubilizing eﬀect of PEG4000 and the high dispersion
state.
4.4. Dose Dependency in In Situ Intestinal Absorption of ACGs.
The dose dependency in the intestinal absorption of ACGs
was examined by administering at a dose of 200μg/mL,
300μg/mL, 500μg/mL (total extract) to the intestinal loop in
rats separately (Table 3). The absorption percentage of ACGs
wasestimatedbythedisappearancepercentagefromtheloop
for 2h, and there is no signiﬁcantly diﬀerence among the
three-dose group (Figure 4).6 Gastroenterology Research and Practice
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Figure 3: Dissolution proﬁles of ACGs and ACGs-SD in PBS (pH 6.8) at 37◦C.Gastroenterology Research and Practice 7
A
b
s
o
r
p
t
i
o
n
 
r
a
t
e
 
(
%
)
Concentration (ug/mL)
200 300 500
Cherimolin-1 in ACGs-SD
Annonacin in ACGs-SD
Squamocin in ACGs-SD
Annonin-vi in ACFs-SD
80
75
70
65
60
55
50
45
40
Figure 4:Intestinalabsorptionofannonacin,squamocin,annonin-
VI and Cherimolin-1 in rats. ACGs-SD was administered at a
dose of 200, 300, 500μg/mL to a 10cm-long jejunum loop and
the intestinal absorption rate (%) was estimated by measuring the
remained amount of ACGs in the loop 2h after administration.
(n = 5).
Table 3: The permeability (Papp, Mean ± SD, n = 6) at diﬀerent
perfusate concentration.
Concentration
(μg ·mL
−1)
Papp ×103 (cm ·s−1) ±SD
Annonacin Squamocin Annonin-
VI
Cherimolin-
I
200 1.29 ±0.12 0.96 ±0.28 0.75 ±0.37 1.18 ±0.23
300 0.92 ±0.23 0.96 ±0.27 0.75 ±0.21 0.79 ±0.38
500 0.69 ±0.31 0.93 ±0.32 0.79 ±0.30 0.75 ±0.29
Table 4: The permeability (Papp, Mean ± SD, n = 6) at diﬀerent site
of intestinal.
Intestine
segment
Papp ×103 (cm ·s−1) ±SD
Annonacin Squamocin Annonin-VI Cherimolin-
I
Duodenum 1.36 ±0.34 1.24 ±0.27 2.28 ±0.29 1.21 ±0.58
Jejunum 1.38 ±0.82 1.30 ±0.27 1.87 ±0.29 1.18 ±0.52
Ileum 1.17 ±0.49 1.14 ±0.31 1.26 ±0.30 2.25 ±0.4
colon 0.95 ±0.45 1.03 ±0.19 1.10 ±0.45 1.59 ±0.31
4.5. Eﬀects of Diﬀerent Intestinal Site on Intestinal Absorption.
The eﬀect of diﬀerent intestinal site on intestinal absorption
of ACGs was examined by administering at a dose of
300μg/mL to the diﬀerent intestinal loop in rats (Table 4).
The absorption percentage of ACGs was comparable among
the four regions (duodenum, jejunum, ileum, and colon
segment). The results showed that there is no signiﬁcant
diﬀerence among diﬀerent intestinal site.
5. Discussion
Oral drug delivery is the simplest and easiest way of
administering drugs. In fact, most drugs are poorly water
soluble drugs, not well absorbed after oral administration.
Comparing with most plant constituents with low oral
bioavailability, ACGs exhibit a broad range of biological
properties, but hardly soluble in water. Drug release is
a crucial and limiting step for oral drug bioavailability,
particularly for drugs with low gastrointestinal solubility and
high permeability. By improving the drug release proﬁle of
these drugs, it is possible to enhance their bioavailability and
reduce side eﬀects [36, 37].
In the present study, we prepared ACGs-SD with
PEG4000 then evaluated the absorption sites of ACGs-SD by
administering into the intestinal loop prepared at diﬀerent
sites along the small intestine and dose dependence in in
situ intestinal absorption. Such study on the intestinal ab-
sorption sites would be expected to prove the adsorption
improvement eﬀect of solid dispersion and reveal the best
absorptionsiteinintestinal.Theabsorptiondatashowedthat
ACGs-SD displayed good absorption in intestinal, the per-
centage of absorption all above 50%. Although the uptake
studyofdiﬀerentsiteofintestinalshowedduodenumhadthe
best permeability, followed by jejunum, ileum, and colon,
there is no signiﬁcant diﬀerence among the four intestinal
sites.
Solid dispersions are one of the most successful strategies
toimprovedrugreleaseofpoorlysolubledrugs.Thesecanbe
deﬁned as molecular mixtures of poor water soluble drugs in
hydrophilic carriers, which present a drug release proﬁle that
is driven by the polymer properties [38].
6. Conclusion
This study clearly revealed that the preparation of solid
dispersions of PEG 4000 with ACGs led to enhanced solu-
bility and bioavailability. The ACGs existed in an amorphous
state. The comparison of dissolution of ACGs and its solid
dispersion with PEG 4000 indicated that the solid dispersion
had a higher release proﬁle. The single-pass intestinal
perfusion studies (SPIPs) in rats also conﬁrmed that ACGs-
SD displayed a good absorption in intestinal. In conclusion,
our results demonstrated that formulation of ACGs with
PEG signiﬁcantly improved the four compounds’ solubility
and dissolution properties; the resulting product also could
improve the absorption of ACGs in intestinal.
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